Together, these results indicate that sorafenib prevents the emergence of EGFR-TKI resistant subpopulations of NSCLC cells through a mechanism involving, at least in part, its combined inhibitory effects on MKNK, STAT3, and MCL1. Here, MCL1 is linked to non-small cell lung carcinoma.